BR112015004110A2 - sistemas e métodos de distribuição de drogas para tratamento de próstata - Google Patents

sistemas e métodos de distribuição de drogas para tratamento de próstata

Info

Publication number
BR112015004110A2
BR112015004110A2 BR112015004110A BR112015004110A BR112015004110A2 BR 112015004110 A2 BR112015004110 A2 BR 112015004110A2 BR 112015004110 A BR112015004110 A BR 112015004110A BR 112015004110 A BR112015004110 A BR 112015004110A BR 112015004110 A2 BR112015004110 A2 BR 112015004110A2
Authority
BR
Brazil
Prior art keywords
drug
bladder
methods
prostate
drug delivery
Prior art date
Application number
BR112015004110A
Other languages
English (en)
Inventor
Giesing Dennis
Original Assignee
Taris Biomedical Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taris Biomedical Llc filed Critical Taris Biomedical Llc
Publication of BR112015004110A2 publication Critical patent/BR112015004110A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/04—General characteristics of the apparatus implanted
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/10—Trunk
    • A61M2210/1078—Urinary tract
    • A61M2210/1085—Bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/16—Male reproductive, genital organs
    • A61M2210/166—Prostate

Abstract

1/1 resumo “sistemas e métodos de distribuição de drogas para tratamento de próstata” métodos, dispositivos e medicamentos que incluem uma droga são fornecidos para uso no tratamento da próstata administrando localmente a droga na bexiga de um paciente para atingir uma concentração sustentada da droga na urina na bexiga suficiente para produzir uma concentração terapêutica da droga na próstata. a droga pode ser distribuída para a bexiga de um dispositivo de distribuição de droga intravesical inserido na bexiga, em que o dispositivo libera continuamente a droga para a urina na bexiga durante um período prolongado de horas ou dias.
BR112015004110A 2012-08-31 2013-09-03 sistemas e métodos de distribuição de drogas para tratamento de próstata BR112015004110A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261696029P 2012-08-31 2012-08-31
PCT/US2013/057841 WO2014036556A2 (en) 2012-08-31 2013-09-03 Drug delivery systems and methods for treatment of prostate

Publications (1)

Publication Number Publication Date
BR112015004110A2 true BR112015004110A2 (pt) 2017-07-04

Family

ID=49162284

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015004110A BR112015004110A2 (pt) 2012-08-31 2013-09-03 sistemas e métodos de distribuição de drogas para tratamento de próstata

Country Status (14)

Country Link
US (2) US9636488B2 (pt)
EP (1) EP2890386A2 (pt)
JP (1) JP6309009B2 (pt)
KR (2) KR20150043508A (pt)
CN (2) CN112516154A (pt)
AU (1) AU2013308465B2 (pt)
BR (1) BR112015004110A2 (pt)
CA (1) CA2882575C (pt)
IL (1) IL237300B (pt)
IN (1) IN2015DN01560A (pt)
MX (1) MX367070B (pt)
RU (1) RU2678308C2 (pt)
SG (1) SG11201501483XA (pt)
WO (1) WO2014036556A2 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2890384B1 (en) 2012-08-31 2021-11-03 TARIS Biomedical LLC Drug delivery systems and methods for treatment of bladder cancer comprising oxaliplatin
RU2678308C2 (ru) 2012-08-31 2019-01-25 ТАРИС Биомедикал ЛЛК Системы доставки лекарственного средства и способы лечения заболевания предстательной железы, включающие применение гемцитабина
DK3035991T3 (da) 2013-08-19 2020-09-21 Taris Biomedical Llc Lægemiddelleveringsindretninger med flere enheder
CA2939979C (en) * 2014-03-06 2023-03-21 Taris Biomedical Llc Drug delivery systems and methods for treatment of bladder cancer with gemcitabine
EP3200801B1 (en) * 2014-10-02 2024-04-24 University of Maryland, Baltimore Methods of treating pancreatic cancer
AU2017261371B2 (en) 2016-05-06 2023-07-06 Taris Biomedical Llc Method of treating lower tract urothelial cancer
SG10201913998YA (en) * 2017-07-25 2020-03-30 Taris Biomedical Llc Methods of treating tumor metastasis
PE20210041A1 (es) 2017-11-08 2021-01-08 Taris Biomedical Llc Metodos de tratamiento y terapia de mantenimiento para el cancer de vejiga con gemcitabina
MX2021001264A (es) 2018-08-01 2021-07-02 Taris Biomedical Llc Métodos para tratar la vejiga hiperactiva con el uso de trospio.
US20220107320A1 (en) 2019-02-15 2022-04-07 Incelldx, Inc. Assaying Bladder-Associated Samples, Identifying and Treating Bladder-Associated Neoplasia, and Kits for Use Therein

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6171298B1 (en) 1996-05-03 2001-01-09 Situs Corporation Intravesical infuser
CA2503193A1 (en) 2002-10-22 2004-05-06 The Biomerix Corporation Method and system for intravesicular delivery of therapeutic agents
US8361490B2 (en) * 2004-09-16 2013-01-29 Theracoat Ltd. Biocompatible drug delivery apparatus and methods
DE102005020314A1 (de) * 2005-05-02 2006-11-09 Infineon Technologies Ag Spannungsversorgungsanordnung zur Versorgung einer ersten elektrischen Last und Verfahren zum Bereitstellen einer elektrischen Leistung
JP5265359B2 (ja) 2005-08-11 2013-08-14 マサチューセッツ インスティテュート オブ テクノロジー 膀胱内薬物送達デバイスおよび方法
CA2650520A1 (en) 2006-04-24 2008-01-31 Gloucester Pharmaceuticals Treatment of ras-expressing tumors
EP1913962A1 (en) * 2006-10-22 2008-04-23 Ophir Perelson Expandable medical device for the treatment and prevention of cardiovascular diseases
CN101616671A (zh) * 2007-01-19 2009-12-30 卫材R&D管理有限公司 胰腺癌治疗用组合物
CA2706384C (en) 2007-12-11 2016-05-31 Massachusetts Institute Of Technology Implantable drug delivery device and methods for treatment of the bladder and other body vesicles or lumens
AU2009246834B2 (en) 2008-04-04 2012-12-06 Lipella Pharmaceuticals, Inc. Treatment of bladder dysfunction using liposomal botulinum toxin
US9486431B2 (en) * 2008-07-17 2016-11-08 Micell Technologies, Inc. Drug delivery medical device
KR101794899B1 (ko) 2008-08-09 2017-11-07 메사츄세츠 인스티튜트 어브 테크놀로지 남성 비뇨생식기 및 주위 조직을 치료하는 방법 및 체내이식형 약물 전달 장치
US8343516B2 (en) 2009-06-26 2013-01-01 Taris Biomedical, Inc. Solid drug tablets for implantable drug delivery devices
US8721621B2 (en) 2009-09-10 2014-05-13 Taris Biomedical, Inc. Systems and methods for deploying devices to genitourinary sites
US9017312B2 (en) 2009-09-10 2015-04-28 Taris Biomedical Llc Implantable device for controlled drug delivery
US8679094B2 (en) 2009-12-17 2014-03-25 Taris Biomedical, Inc. Implantable device with intravesical tolerability and methods of treatment
DK2525777T3 (da) 2010-01-20 2019-07-01 Urogen Pharma Ltd Materiale og fremgangsmåde til at behandle interne hulrum
US20110218488A1 (en) 2010-03-05 2011-09-08 Taris Biomedical, Inc. Systems and Methods for Implanting Devices in the Bladder and Other Genitourinary Sites
EP3741330A3 (en) 2010-08-05 2020-12-30 TARIS Biomedical LLC Ureteral stent drug delivery device
WO2012048104A1 (en) 2010-10-06 2012-04-12 Taris Biomedical, Inc. Implantable drug delivery device with bladden retention feature
EP2624875A1 (en) 2010-10-06 2013-08-14 Taris Biomedical, Inc. Time-selective bioresorbable or collapsible drug delivery systems and methods
US8979797B2 (en) 2010-12-16 2015-03-17 Ams Research Corporation High pressure delivery system and method for treating pelvic disorder using large molecule therapeutics
CA2823783C (en) 2011-01-10 2023-03-21 Taris Biomedical, Inc. Lidocaine regimen for the use of sustained treatment of bladder pain and irritative voiding
AU2012211960B2 (en) * 2011-02-04 2016-12-01 Taris Biomedical Llc Implantable device for controlled release of low solubility drug
US20150005595A1 (en) 2011-12-30 2015-01-01 Kibur Medical, Inc. Implantable devices and methods for evaluation of active agents
US10058688B2 (en) 2012-05-09 2018-08-28 Massachusetts Institute Of Technology Medicament, method, and drug delivery device for treatment of ovarian cancer
RU2678308C2 (ru) 2012-08-31 2019-01-25 ТАРИС Биомедикал ЛЛК Системы доставки лекарственного средства и способы лечения заболевания предстательной железы, включающие применение гемцитабина
EP2890384B1 (en) 2012-08-31 2021-11-03 TARIS Biomedical LLC Drug delivery systems and methods for treatment of bladder cancer comprising oxaliplatin
CA2883855C (en) 2012-09-18 2020-09-15 Taris Biomedical Llc Drug delivery systems and methods for treatment of bladder voiding dysfunction|and other lower urinary tract disorders by using trospium
WO2014145638A1 (en) 2013-03-15 2014-09-18 Taris Biomedical, Inc Drug delivery devices with drug-permeable component and methods
US9814671B2 (en) 2013-03-15 2017-11-14 Taris Biomedical Llc Drug delivery devices and methods for drug delivery
US9301926B2 (en) 2013-04-10 2016-04-05 Massachusetts Institute Of Technology Local drug delivery devices and methods for treating cancer
DK3035991T3 (da) 2013-08-19 2020-09-21 Taris Biomedical Llc Lægemiddelleveringsindretninger med flere enheder
CA2939979C (en) 2014-03-06 2023-03-21 Taris Biomedical Llc Drug delivery systems and methods for treatment of bladder cancer with gemcitabine

Also Published As

Publication number Publication date
EP2890386A2 (en) 2015-07-08
US10406335B2 (en) 2019-09-10
MX2015002452A (es) 2015-06-05
MX367070B (es) 2019-08-05
IL237300A0 (en) 2015-04-30
CA2882575A1 (en) 2014-03-06
US20170203085A1 (en) 2017-07-20
CA2882575C (en) 2020-05-26
AU2013308465A1 (en) 2015-03-05
KR20150043508A (ko) 2015-04-22
KR102383496B1 (ko) 2022-04-08
IL237300B (en) 2020-02-27
JP2015528469A (ja) 2015-09-28
WO2014036556A2 (en) 2014-03-06
CN104812395A (zh) 2015-07-29
JP6309009B2 (ja) 2018-04-11
US20150165177A1 (en) 2015-06-18
RU2678308C2 (ru) 2019-01-25
WO2014036556A3 (en) 2014-04-17
RU2015109298A (ru) 2016-10-20
IN2015DN01560A (pt) 2015-07-03
AU2013308465B2 (en) 2018-05-17
SG11201501483XA (en) 2015-03-30
CN112516154A (zh) 2021-03-19
KR20200120774A (ko) 2020-10-21
US9636488B2 (en) 2017-05-02

Similar Documents

Publication Publication Date Title
BR112015004110A2 (pt) sistemas e métodos de distribuição de drogas para tratamento de próstata
BR112015005351A2 (pt) sistemas para distribuição de drogas e métodos para tratamento de disfunção de esvaziamento da bexiga e outros distúrbios do trato urinário inferior
BR112015003836A2 (pt) sistemas e métodos para distribuição de drogas para tratamento de câncer de bexiga
MX2016011333A (es) Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.
MX352824B (es) Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado común e inflamación.
BR112015027282A8 (pt) formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet
MX2021004546A (es) Composiciones de suministro de farmaco implantables y metodos de uso de las mismas.
MX2013013809A (es) Dispositivos expandibles con revestimiento de una composicion de paclitaxel.
AR069704A1 (es) Sistema de administracion de rnai de interferencia y usos del mismo
EA202091999A2 (ru) Применение ингибиторов dpp iv
MX2011007589A (es) Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20.
WO2009105432A3 (en) Devices and methods for delivery of a therapeutic agent through a pneumostoma
AR089862A1 (es) USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
MX2013008175A (es) Composiciones farmacéuticas para suministro tópico de fotosensibilizadores y usos de los mismos.
EA201491702A1 (ru) Оптимизированные терапевтические агенты для подкожного введения
MX2018013715A (es) Composiciones acuosas de capsaicinoides que comprenden un analgesico y un vehiculo acuoso, y uso de las mismas para el tratamiento del dolor.
BR112013010829B8 (pt) Composição farmacêutica intravenosa para proporcionar alívio da dor e/ou da inflamação
BR112012030641B8 (pt) Usos e composições para terapia farmacêutica oral
PE20181332A1 (es) Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos
MX2015011775A (es) Uso de levocetirizina y montelukast en el tratamiento de anafilaxis.
BR112013027010A2 (pt) método de produzir substâncias com gás supersaturado, dispositivo para sua entrega trasdérmica, e seus usos
MX2013013808A (es) Dispositivos expandibles con revestimiento de una composicion de rapamicina.
AR079000A1 (es) Terapia anticancerosa dirigida a celulas madre cancerosas resistentes a las drogas
BR112013027006A2 (pt) método de produzir substâncias com gás supersaturado, dispositivo de distribuição transdérmica do mesmo
BR112014005653A2 (pt) uso de 4-amino-5-fluoro-3[6-(4-metilpiperazin-1-il)-1h-benzimidazol-2-1l]1h-quinolin-ona no tratamento de câncer de em pacientes com insuficiência hepática moderada

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICA??O DE DEVOLU??O DO PEDIDO EM FUN??O DA REVOGA??O DO ART. 229-C DA LEI N? 9.279, DE 1996, POR FOR?A DA LEI N? 14.195, DE 2021

B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.21 NA RPI NO 2649 DE 13/10/2021 POR TER SIDO INDEVIDA.

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]